Henry Schein (HSIC) Aandelenoverzicht
Henry Schein, Inc. levert producten en diensten voor de gezondheidszorg aan tandartsen en artsen over de hele wereld. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
HSIC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Henry Schein, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$73.80 |
| 52 Week Hoogtepunt | US$89.29 |
| 52 Week Laag | US$61.95 |
| Bèta | 0.88 |
| 1 maand verandering | 0.14% |
| 3 maanden verandering | -2.23% |
| 1 Jaar Verandering | 14.49% |
| 3 jaar verandering | -6.74% |
| 5 jaar verandering | -7.66% |
| Verandering sinds IPO | 1,197.58% |
Recent nieuws en updates
HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside
Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.Recent updates
HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside
Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside
The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop. Analyst Commentary Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.
Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power
Catalysts About Henry Schein Henry Schein is a global distributor of dental and medical products and services with growing software, specialty and value-added solutions for healthcare providers. What are the underlying business or industry changes driving this perspective?HSIC: Steadier Dental Demand And CEO Transition Will Support Balanced Outlook
Analysts have nudged their fair value estimate for Henry Schein up from $78.14 to $83.21, citing higher Street price targets and commentary about steadier organic growth and improving dental demand as the main supports for the updated view. Analyst Commentary Recent Street research on Henry Schein leans constructive, with several firms lifting price targets and, in one case, upgrading the rating as sentiment around dental demand and organic growth improves.HSIC: Revised Assumptions And CEO Transition Will Support Balanced Earnings Outlook
Analysts have increased their price target on Henry Schein by US$7, citing updated assumptions around revenue growth, margins, and future P/E levels that contribute to a revised valuation view. Analyst Commentary Recent research behind the US$7 upward move in the price target focuses on refreshed assumptions for Henry Schein’s revenue trajectory, margin profile, and future P/E levels.HSIC: Q3 Beat And CEO Transition Will Support Range-Bound Earnings Momentum
Narrative Update: Henry Schein The analyst price target for Henry Schein has moved slightly higher by about US$0.50, as analysts point to recent price target increases and a "clean beat" in Q3 that they see as supporting a modestly higher fair value while still viewing the shares as range bound. Analyst Commentary Recent Street commentary on Henry Schein points to a mixed setup, with some bullish analysts nudging price targets higher on the back of Q3 execution and others still reluctant to see a clear path out of the stock's trading range.HSIC: Q3 Beat And AI Partnerships Will Support Range-Bound Earnings Momentum
Analysts have raised their price target on Henry Schein to US$75 from US$71, citing a clean Q3 earnings beat that they view as supporting the recent share price strength, while also questioning how much further the stock can advance beyond its recent trading range. Analyst Commentary Bullish Takeaways Bullish analysts view the Q3 result as a clean beat, which they see as supporting the recent share price move and giving the higher US$75 target some fundamental backing.HSIC: Q3 Beat And Buybacks Will Support Range-Bound Earnings Momentum
Analysts have modestly raised their price target on Henry Schein to approximately $75, reflecting a slightly higher fair value and future price-to-earnings multiple following a clean Q3 beat, even as they remain cautious about the stock meaningfully breaking out of its recent trading range. Analyst Commentary Street research following the Q3 report reflects a mix of cautious optimism and ongoing skepticism about Henry Schein's near term upside potential.Henry Schein Can Make Your Portfolio Smile
Dec 05HSIC: Q3 Beat And Capital Returns Will Support Measured Earnings Momentum
Analysts modestly raised their price target on Henry Schein to $75 from $71, citing a clean Q3 beat that supports recent share gains while still questioning the stock's ability to break out above its historically defined trading range. Analyst Commentary Analysts highlight that the latest quarter delivered a clean beat versus expectations, reinforcing confidence in Henry Schein's ability to execute on its operating plan despite macro and industry headwinds.HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum
Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook
Henry Schein’s analyst price target has increased from $73.23 to $75.15 per share, reflecting analysts’ confidence in improving margins and strategic initiatives following recent earnings results. Analyst Commentary Following the company's recent performance and updated guidance, research analysts have issued new commentary highlighting both upward momentum and remaining concerns regarding Henry Schein's outlook.Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Aug 08
Here's Why Shareholders Should Examine Henry Schein, Inc.'s (NASDAQ:HSIC) CEO Compensation Package More Closely
May 16Henry Schein Looks Bullish (Technical Analysis)
Mar 11Henry Schein: An Industry Leader That Offers Some Upside From Here
Mar 04Henry Schein: The Kind Of Business I Like But No Margin Of Safety Now
Dec 10Henry Schein: Another Day, Another Purchase
Nov 20
Critical Acquisitions And High-Growth Product Expansion Set To Transform Dental Giant
Expansion into high-growth products and strategic acquisitions aimed at increasing gross margins through improved integration and efficiency.Henry Schein: Acquisition Strategy Isn't Pulling Its Economic Weight
May 23Rendement voor aandeelhouders
| HSIC | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -5.7% | 5.3% | -0.2% |
| 1Y | 14.5% | -3.0% | 27.6% |
Rendement versus industrie: HSIC overtrof de US Healthcare industrie, die het afgelopen jaar een rendement -3 % opleverde.
Rendement versus markt: HSIC presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 27.6 % opleverde.
Prijsvolatiliteit
| HSIC volatility | |
|---|---|
| HSIC Average Weekly Movement | 3.8% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabiele aandelenkoers: HSIC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van HSIC is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1932 | 25,000 | Fred Lowery | www.henryschein.com |
Henry Schein, Inc. levert producten en diensten voor de gezondheidszorg aan tandartsen en artsen over de hele wereld. Het bedrijf is actief via de segmenten Global Distribution and Value-Added Services, Global Specialty Products en Global Technology. Het segment Global Distribution and Value-Added Services distribueert infectiebestrijdingsproducten, handstukken, preventieve middelen, afdrukmaterialen, composieten, anesthetica, tanden, gips, acrylaat, articulatoren, schuurmiddelen, PBM-producten, merk- en generieke geneesmiddelen, vaccins, chirurgische producten, diagnostische tests, tandartsstoelen, toedieningseenheden en lampen, digitale tandheelkundige laboratoria, röntgenbenodigdheden en -apparatuur, en high-tech en digitale restauratieapparatuur, evenals reparatiediensten voor apparatuur, financiële diensten op non-recourse basis, permanente educatie voor artsen, consulting en andere diensten.
Henry Schein, Inc. Samenvatting
| HSIC fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$8.47b |
| Inkomsten(TTM) | US$398.00m |
| Inkomsten(TTM) | US$13.18b |
Is HSIC overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HSIC resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$13.18b |
| Kosten van inkomsten | US$9.08b |
| Brutowinst | US$4.11b |
| Overige uitgaven | US$3.71b |
| Inkomsten | US$398.00m |
Laatst gerapporteerde inkomsten
Dec 27, 2025
Volgende inkomensdatum
May 05, 2026
| Winst per aandeel (EPS) | 3.47 |
| Brutomarge | 31.14% |
| Nettowinstmarge | 3.02% |
| Schuld/Eigen Vermogen Verhouding | 64.7% |
Hoe presteerde HSIC op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/04/30 17:34 |
| Aandelenkoers aan het einde van de dag | 2026/04/29 00:00 |
| Inkomsten | 2025/12/27 |
| Jaarlijkse inkomsten | 2025/12/27 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Henry Schein, Inc. wordt gevolgd door 32 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jeffrey Johnson | Baird |
| Glen Santangelo | Barclays |
| Lawrence Marsh | Barclays |